T-DXd Tolerability in Community-Treated HER2-Low Metastatic Breast Cancer: What Real-World Practice Is Showing

TheBrief**

Trastuzumab Deruxtecan (T-DXd) is now increasingly emerging as the preferred choice for HER2-low metastatic breast cancer patients, and initial experiences in the community environment show that this drug can be administered in a safe and effective manner with proper precautions in place. With the use of T-DXd becoming widespread across the community setting and not confined to major academic medical centers, the emphasis on patient care becomes essential in terms of ensuring proper monitoring, patient education, and timely management of any adverse events, particularly those involving the lungs.

Why It Matters**

Low HER2 metastatic breast cancer represents an intermediate category in which tumors do not express HER2 according to established criteria, yet there is a low expression level of HER2 receptors that can be utilized for therapy. The importance of such nuances lies in the fact that it allows expanding the possibilities of treating patients beyond the use of conventional chemotherapy and hormone-based therapy. T-DXd is an ADC treatment in which the drug uses an anti-cancer receptor as a carrier to target its delivery directly to cancer cells with a link specifically intended for release from the drug inside the cancer cell. In a number of patients with advanced metastatic cancer progression despite prior treatment, T-DXd has shown great potential for tumor regression, symptomatic improvement, and extended disease-free intervals.

Tolerability of medications in clinical practice is important since the vast majority of patients will receive their treatments not in academic settings but in community facilities. The latter will need to consider a wider variety of health issues as community settings will include many elderly individuals, individuals with poly-morbidities, and even those patients who may have undergone multiple therapies.

Why community delivery changes the conversation**

The results of clinical trials reveal the efficacy and effectiveness of medications under strictly regulated conditions, whereas community settings reflect their actual performance in real life. The average clinic schedule includes balancing conflicting needs such as infusion chairs, pre-approvals, imaging scans, workforce shortage, and sudden influxes of new patients. However, the use of T-DXd brings more challenges since consistent follow-up and an strong focus on safety and adverse effects are required.

Interstitial lung disease (ILD) or pneumonitis is one of the potential side effects of T-DXd; however, it is extremely dangerous since early diagnosis may not be possible. This is the only factor that should be considered when developing the workflow in the clinic. While a practice cannot afford large-scale academic resources to handle the potential problem, the protocol is quite simple: assessing the baseline status, asking specific questions during appointments, having rapid imaging for any signs of problems, and immediately interrupting the treatment course if necessary.

The ripple effects extend beyond the clinic**

As the usage of T-DXd grows, it affects payment policies, staffing strategies, and administration procedures. A number of clinics will have to improve their policies regarding procurement, storage, and proper handling of the drug. They might even have to develop reliable protocols for supportive care such as nausea management, fatigue reduction, and laboratory testing. Once such a system is implemented, patients will not be shuttled from urgent care facilities to emergency rooms and back again.

Who It Affects**

Patients with metastatic HER2-low breast cancer can most benefit, particularly if they have already been treated with standard therapies and now require more advanced therapies. Often, this group of individuals reaches a point where they require two things: effective management of their disease and a regimen that remains acceptable. There are patients who need treatment but still continue working, caring for family members, and traveling, so all these factors become essential to their decision as much as the drug itself.

These patients tend to be extremely heterogeneous, and that explains different tolerability issues they may experience in practice. Patients could have shortness of breath due to the presence of asthma, history of chest radiation, smoking-related changes in the lungs, or previous respiratory infections. There are patients with anemia caused by prior chemotherapy, nausea due to prior treatment, or fatigue associated with anemia, sleep deprivation, or depression. In many cases, community practices are better equipped to appreciate all these clinical characteristics.

Clinicians and staff carry much of the operational load**

Community oncologists, APPs, and nurses in oncology are affected since T-DXd therapy involves proper assessment and decision-making about doses. Nurses play an important role in educating patients, answering calls from the patients, and noting any symptoms reported by them. Pharmacists and infusion nurses verify, prepare, and administer drugs. The back-office staff plays an important role in accessing the drug to ensure it is not delayed by weeks.

Primary care providers and specialists also form the circle of care. This means that patients may go to the family physician after coughing, while others may visit urgent care centers if experiencing fever and breathing problems. Understanding the fact that T-DXd causes pneumonitis would help improve communication.

Health systems and payers feel the pressure too**

Infusion centers will have to account for extended appointments, regular laboratory appointments, and even same-day assessments during flare-ups. There is an increased need for imaging availability, which poses practical restrictions for most regions. Health insurance companies and utilization management departments may demand proof of HER2-low classification and treatment history, resulting in additional paperwork and delays in initiating therapy.

What Changes**

T-DXd’s arrival into everyday practice makes clinics more rules-oriented, particularly regarding lung protection, nausea prevention, and fast triaging. It is not about making treatment inflexible; it is about ensuring its consistency so that no patient is missed in case he or she develops any symptoms.

1) Increased need for baseline respiratory assessment and vigilance**

Given that ILD or pneumonitis is the most important potential risk, the first thing that needs to happen at a clinic is to establish a standardized protocol for baseline evaluation of patients’ lungs before the first dose.

The first step is to make sure that patients know the meaning of a “new” symptom and the importance of recognizing it. For example, any new coughing, difficulty breathing, feeling of pressure in the chest area, fever of unknown origin, and decreased capacity for physical exertion should prompt an urgent phone call. The key point for community practices here is that there is no need to scare patients off, but they need to be told that this will protect their lungs and ensure continued treatment options.

It is also beneficial to develop a step-by-step plan of actions. This will help clinics respond to the problem much faster since each practice has its own set of standard questions to ask patients and determine who should see them as soon as possible and order imaging studies.

2) More structured monitoring and rapid management protocols**

T-DXd needs proactive monitoring of patients more so than reactive monitoring. Aside from respiration assessments, the community team often makes it a practice to ensure that the basic steps are taken, such as performing symptom checklist screening during visits, lab work, and follow up quickly after first or second doses.

Nausea and appetite support**

Nausea is a side effect seen in many types of chemotherapy medications, and T-DXd may prove difficult if preventive measures are not put in place from day one. An effective strategy involves providing nausea prevention medication at a set time during the treatment period, not just when necessary, and making timely adjustments for those who continue to have trouble. It also helps to give patients practical tips that are effective, such as eating frequently and hydrating well.

Fatigue that affects daily life**

Fatigue may develop slowly and be disheartening, particularly for those who have been physically tired from previous treatments. Health care providers may assist their patients in determining any possible causes that could be reversed through anemia, insomnia, pain, depression, lack of physical exercise, and nutritional deficiencies. Minor changes, including taking short walks and engaging in mild exercises, may enhance daily activities.

Blood counts and infection risk**

Similar to many other chemotherapeutic regimens, treatment with T-DXd may lead to changes in your blood counts, which can increase your chances of getting an infection and necessitate dose reduction or deferral. Community-based practices usually perform monitoring of the patient’s blood counts as per protocol and take action upon detecting either neutropenia or anemia. It is crucial that patients know how to recognize fever.

Dose interruption and dose reduction as normal tools**

Holding or reducing doses should not be viewed as failures; they are simply part of safe administration. Many patients will go on to achieve successful treatment following alterations in supportive therapy and dosing. The most important element is consistency: noting symptoms, grading appropriately, and using dose modifications in a manner that is consistent and understandable by the patient.

3) Expanded staff training and patient education**

T-DXd requires much from the care team; therefore, the investment in practical training shows its results instantly. Practical training for nurses and pharmacists should include not only information on which questions to ask but also tips on documentation and interpretation of “red flags,” as well as the correct reaction of the facility as a whole. It would be important to train staff how to communicate with patients about the drug’s effect in non-medical language.

It is crucial to prepare easy-to-use literature for patients. The following items may be included: expected side effects, list of urgent symptoms, number to call in case of an emergency in after-hours and steps to take in case they require emergency treatment. Clinics could conduct a quick follow-up call during the first week after administration, when necessary.

4) Operational and financial adaptations**

Regarding workflow, T-DXd is successfully implemented in the community setting when practices consider the drug as a “program” instead of an infusion to be ordered. This entails streamlining pre-infusion processes: obtaining appropriate documentation regarding HER2-low, gathering data on baseline symptoms, coordinating labs and imaging studies, and arranging antiemetic regimens prior to infusion days.

Authorization and insurance issues might become the invisible obstacle to delivering timely care. Practices have been known to facilitate access by making a checklist of necessary documents and assigning a single person in charge of obtaining authorization and reimbursements. Those who manage to streamline these procedures minimize treatment delays and alleviate patient burden.

Infusion capacity is essential in small-scale facilities. In case chair time becomes scarce, practices may consider revising scheduling templates, bundling educational meetings, or conducting regular phone calls instead of increasing the number of office visits.

Looking Ahead**

As community experience grows, practice patterns will likely become more standardized and more confident. Expect clearer consensus on baseline workups, symptom screening frequency, and step-by-step management for suspected ILD or pneumonitis. Over time, clinics may adopt templated documentation tools, automated symptom questionnaires, or rapid imaging pathways to reduce delays.

Biomarker testing may continue to refine who benefits most from HER2-low targeted therapy. As pathology and testing workflows improve, clinicians may identify patients earlier and reduce uncertainty around eligibility. Meanwhile, ongoing research into newer ADCs and supportive care strategies may eventually improve tolerability and simplify delivery.

For now, the practical message for community clinicians is straightforward. T-DXd can offer meaningful benefit for patients with HER2-low metastatic breast cancer, and community practices can deliver it effectively when they build strong safety habits: baseline respiratory review, consistent symptom screening, fast evaluation of new cough or shortness of breath, and proactive supportive care for nausea, fatigue, and blood count changes.

References

1. Modi S, Jacot W, Iwata H, et al. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature Medicine. 2025;31(12):4205–4213. doi:10.1038/s41591-025-03981-4. Available from: https://pubmed.ncbi.nlm.nih.gov/41062831
2. U.S. Food and Drug Administration. ENHERTU® (fam-trastuzumab deruxtecan-nxki) for injection: Prescribing Information (Revised 12/2025). FDA. 2025. Available from: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2025/761139s038s042lbl.pdf
3. Wekking D, Porcu M, Pellegrino B, et al. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open. 2023;8(6):102043. doi:10.1016/j.esmoop.2023.102043. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10679891
4. Miranda LS, Sousa MJ, Braga MM, et al. Trastuzumab deruxtecan in previously treated HER2-low metastatic breast cancer: Real-world multicentric study in the Portuguese population. Cancers (Basel). 2025;17(12):1911. doi:10.3390/cancers17121911. Available from: https://www.mdpi.com/2072-6694/17/12/1911